Member Info for daveycaferacer

In connection with the Offering, Chi-Med, its officers and directors and the selling shareholder have agreed to a 90-day lock-up on sales or transfers of Ordinary Shares, ADSs or equity-linked securities. Chi-Med remains committed to its previously announced proposed listing of its Shares on The Stock Exchange of Hong Kong ("SEHK") and a potential concurrent global offering of its Ordinary Shares which Chi-Med may pursue following the expiration of such lock-up period. Chi-Med's listing application and potential concurrent global offering are subject to, among other things, the final approval of the SEHK, the final decision of the Chi-Med board of directors, market conditions and other factors. Accordingly, Chi-Med's shareholders and potential investors should be aware that there is no assurance that the listing and the potential concurrent global offering will take place or as to when it may take place. Chi-Med will provide a further update on the timing as appropriate.

https://www.chi-med.com/secondary-offering-of-ads/

I wonder of this is as a result of a delay in the HK Listing?

it's reduced significantly since yesterday and as I only buy and will be holding for another 10 years it's not too much of an issue. With the platform I use I can get a real-time price for both ADR's and UK listed shares, so can decide on a deal by deal basis. There's also a currency play here of course. Sterling futures are looking at 1.31-1.32 going into next year which may mean it's worth paying the extra spread on UK shares. Ether way I forecast Chi-Med's share price to be many multiples of today in the next 10 yrs so it's probably irrelevant anyway.

I will only purchase ADRs as the current 8% spread makes thevUK listed shares too expensive

An interesting article just published discussing the China-U.S. trade war and how drugs will continue to be tariff free

https://www.investors.com/news/technology/china-trade-war-biotech-companies-medtech-companies/

I have just acquired more shares and paid 454 pence for them, although I am not enthusiastic about the spread which is still in excess of 6%. I imagine this is putting off many potential Buyers and Investors.

I agree Jatw and we had similar speculation at both NASDAQ fundraisings so it just seems to be a standard thing with these types of offerings

Interesting Warwis, I just saw that, speculation I think

(Bloomberg) -- Hutchison China MediTech Ltd., a cancer drug developer backed by billionaire Li Ka-shing, is delaying the launch of its Hong Kong share sale that could raise about $500 million, people with knowledge of the matter said.

https://finance.yahoo.com/news/li-ka-shing-backed-cancer-055641185.html

https://www.trinitydelta.org/research-notes/surufatinib-on-track-for-potential-2020-china-approval/

I've never seen a Company issue shares which are then immediately registered to a creditor in lieu of cash payments, this is shocking and clearly demonstrates the difficulties the Company is in.

thankyou amones, I was unaware of this interesting initiative......

Nice article on Biotech in today's WSJ including mention of Chi-Med

https://www.wsj.com/articles/china-biotechs-lure-industry-talent-in-the-u-s-11560690000?emailToken=67ee6c851f54ba288bee42d414b90b488h22xffARTB821KS8UM38ywU6MbvZmY7EYMeAKba72EN1cUtB7FHSMsmxMdgrNV3fi1aX0XLD8SSNvj79vAfD63hyc7BSJzs4/QjRGH1wMk%3D&reflink=article_whatsapp_share

A small amount of coverage on Surufatinib in today's Times Newspaper

https://www.thetimes.co.uk/article/drugs-company-calms-nerves-in-an-edgy-market-72xglq2r2?_ga=2.229305247.2083440907.1560618860-368432237.1560618860

https://www.trinitydelta.org/research-notes/impressive-data-means-sanet-ep-trial-stopped-early/

When the NDA submission was announced for Fruquintinib the share price went down, when the approval came through and I happened to be standing near the HWL building in Central at the time, the share price also went down.

net and non-net forecast peak sales in China is quite small @ circa $40m but billiary tract will be the bigger opportunity, hopefully with a Phase 3 data readout later this year

I agree Jat2 re the fund raise, great timing because it proves the Company can deliver more than one best of first in class asset and will give potential Investors confidence this is just the beginning

Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that the independent Data Monitoring Committee ("IDMC") of the Phase III pivotal study of surufatinib in advanced neuroendocrine tumors - extra-pancreatic ("SANET-ep") has completed a planned interim analysis. The IDMC determined that the study has already met the pre-defined primary endpoint of progression free survival ("PFS") and as a result the study will be stopped.

Chi-Med will now arrange for a pre-New Drug Application ("NDA") meeting with the China National Medical Products Administration (NMPA)

My interpretation is that the interim data is so good we can proceed straight to NDA

Hansoh Pharma IPO today, currently up 40% on the day, it would be nice to see something similar with Chi-Med

Clearly Hong Kong has a huge appetite for Biotech

https://www.scmp.com/business/companies/article/3014265/ex-chemistry-teacher-zhong-huijuan-poised-become-chinas-third

The Morgan Stanley China Summit presentation has been posted to the Chi-Med website

https://www.chi-med.com/wp-content/uploads/2019/06/pre20190531.pdf

I think we are due an Elunate sales update with the H1 results, and the Company may have a view by then as to the chances of getting on the NDRL, which will a a major step forward.